Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child.
Brent
R L
RL
Thomas Jefferson University and du Pont Hospital for Children, Wilmington, Delaware 19899, USA. rbrent@nemours.org
D000818:Animals; D001942:Breast Feeding; D015197:Carcinogenicity Tests; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D007555:Isoxazoles / Q000009:adverse effects* / Q000493:pharmacokinetics; D000077339:Leflunomide; D008297:Male; D018811:Maternal Exposure; D009152:Mutagenicity Tests; D018812:Paternal Exposure; D011247:Pregnancy; D011725:Pyridines / Q000037:antagonists & inhibitors; D013723:Teratogens
D007166:Immunosuppressive Agents; D007555:Isoxazoles; D011725:Pyridines; D013723:Teratogens; D000077339:Leflunomide